Top Page
Uscom Limited
(Sydney:UCM)
Uscom Limited (UCM) vs. iShares MSCI Australia ETF (EWA)
Uscom Limited Business Overview & Revenue Model
Uscom Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.58M | 2.58M | 3.73M | 2.66M | 2.51M | 3.86M |
| Gross Profit | 2.23M | 2.23M | 3.12M | -1.03M | -1.21M | 781.70K |
| EBITDA | -3.06M | -3.06M | -1.51M | -2.50M | -1.84M | -833.84K |
| Net Income | -3.30M | -3.30M | -2.07M | -2.59M | -1.97M | -924.24K |
Balance Sheet | ||||||
| Total Assets | 3.25M | 3.25M | 5.13M | 5.18M | 7.99M | 5.33M |
| Cash, Cash Equivalents and Short-Term Investments | 966.66K | 966.66K | 2.52M | 2.18M | 4.70M | 1.71M |
| Total Debt | 2.26M | 2.26M | 989.28K | 1.09M | 1.31M | 1.43M |
| Total Liabilities | 3.29M | 3.29M | 2.07M | 2.14M | 2.06M | 2.26M |
| Stockholders Equity | -38.22K | -38.22K | 3.06M | 3.04M | 5.94M | 3.08M |
Cash Flow | ||||||
| Free Cash Flow | -2.72M | -2.72M | -1.22M | -1.58M | -1.08M | 21.63K |
| Operating Cash Flow | -2.71M | -2.71M | -1.16M | -1.42M | -967.51K | 54.98K |
| Investing Cash Flow | -68.78K | -68.78K | -57.55K | -151.94K | -115.31K | -33.35K |
| Financing Cash Flow | 1.21M | 1.21M | 1.57M | -952.96K | 4.05M | -281.87K |
Uscom Limited Technical Analysis
Uscom Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$29.98M | -4.81 | -58.27% | ― | -7.20% | 28.70% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$27.44M | -2.92 | -103.74% | ― | 14.84% | 39.64% | |
45 Neutral | AU$32.33M | -5.96 | -513.22% | ― | -34.06% | 75.47% | |
39 Underperform | AU$3.12M | -0.91 | -218.52% | ― | -30.80% | -38.95% | |
38 Underperform | AU$5.39M | -3.55 | ― | ― | ― | -55.00% | |
37 Underperform | AU$7.53M | -0.64 | -1476.79% | ― | -2.82% | 32.47% |
Uscom Limited Corporate Events
Uscom Limited, a leader in medical technology, has announced its FY2025 results and outlined drivers for FY2026. The company has achieved significant milestones, including global clinical adoption and sales in 52 countries, supported by over 1,200 peer-reviewed publications. Uscom’s strategic partnership with Foxconn for manufacturing and global distribution is expected to enhance its market position, focusing on high-margin products and expanding its digital and wireless technology offerings.
Uscom Limited has announced the results of a recent meeting where a resolution was passed to approve the disposal of the company’s main undertaking. The resolution was decided by a poll, with 59.86% voting in favor and 40.14% voting against, indicating a significant decision that could impact the company’s future operations and strategic direction.
Uscom Limited is facing a challenging financial situation, exacerbated by global events such as COVID-19, geopolitical tensions, and trade wars, which have significantly impacted its revenue and led to consecutive years of losses. The company has decided to sell its assets to clear debts and provide a path forward for creditors, while shareholders will retain their interest in the ASX-listed entity. This strategic move aims to ensure the continuation of Uscom’s life-saving technologies and potentially leverage its tax losses for future business opportunities.
Uscom Limited reported a challenging first quarter with a decrease in customer receipts and cash on hand, attributed to global economic uncertainties such as US tariff wars and shifts in European public spending. Despite these challenges, the company remains optimistic about the long-term value of its cardiovascular and pulmonary technologies, which address major health issues. Uscom continues to focus on compliance with global regulatory demands while anticipating a normalization of commercial environments to support its growth.
Uscom Limited has announced its Annual General Meeting of Shareholders, scheduled for November 27, 2025, in Sydney. The company will not send physical copies of the meeting notice, opting instead for electronic distribution. Shareholders are encouraged to participate and vote on resolutions, either in person or via proxy forms, which must be submitted by November 25, 2025. This approach underscores Uscom’s commitment to digital engagement and efficient shareholder communication.
Uscom Limited has announced its 2025 Annual General Meeting (AGM) scheduled for November 27, 2025, in Sydney. Key agenda items include the consideration of the company’s financial report for the year ending June 30, 2025, the adoption of the remuneration report, and the re-election of Mr. Brett Crowley as a director. The remuneration report, which outlines the company’s policies on director and executive compensation, will be presented for an advisory vote. The re-election of Mr. Crowley, an independent non-executive director, is recommended by the board. These resolutions reflect Uscom’s commitment to transparency and governance, potentially impacting shareholder confidence and the company’s strategic direction.
Uscom Limited has announced a General Meeting to seek shareholder approval for the sale of its main undertaking, Uscom Sng Pte. Ltd, to AXO Medtech VCC. This strategic move is driven by Uscom’s ongoing financial challenges, including sustained losses and negative cash flow, which have hindered its ability to raise capital and develop its business. The sale is expected to provide the necessary capital for Uscom’s operations to become profitable, with AXO Medtech VCC intending to continue Uscom’s current business operations, retain employees, and enhance global operations.
Uscom Limited has announced an agreement to sell its entire business and assets to AXO Medtech VCC, a Singapore-based investment company, subject to shareholder approval. This strategic move aims to address Uscom’s financial difficulties and enable the business to raise necessary capital for transformation into a profitable entity. The sale includes all shares in its subsidiary, UCM SNG, for $2.591 million, which will be settled by transferring existing liabilities. AXO plans to continue Uscom’s operations, retain employees, and raise capital to expedite global expansion. The transaction is expected to be completed by late November 2025, pending shareholder approval.
Uscom Limited, a company listed on the Australian Securities Exchange (ASX), has had its securities suspended from quotation due to inadequate financial conditions. The ASX determined that Uscom Limited breached Listing Rule 12.2 after reviewing the company’s annual financial statements and the auditor’s disclaimer of opinion. The suspension will remain in effect until Uscom Limited complies with the ASX’s listing rules and it is deemed appropriate for its securities to be reinstated.
Uscom Limited has released its Corporate Governance Statement for the financial year ending June 30, 2025, detailing its adherence to the ASX Corporate Governance Council’s Principles and Recommendations. The company emphasizes its commitment to high standards of corporate governance, ethical conduct, and shareholder value creation. The statement outlines the roles and responsibilities of the Board and senior management, highlighting the absence of a formal diversity policy due to the company’s size and development stage. Uscom plans to establish a skills matrix and formal evaluation processes in the next reporting period, reflecting its ongoing efforts to enhance governance practices.
Uscom Limited has released its Corporate Governance Statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability in management and oversight. This disclosure is expected to reinforce stakeholder confidence and support Uscom’s strategic positioning in the medical technology sector.